Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

Recruiting now

Conditions studied: Polycythemia Vera

In brief

The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.

Key facts

Study ID: NCT06743035
Run by: iOMEDICO AG
People needed: 200
Starts: 2024-12-03
Expected to finish: 2029-07-01
Last updated by the study team: 2026-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18 years
Confirmed diagnosis of PV without symptomatic splenomegaly
Indication and decision for treatment with ropeginterferon alfa-2b in accordance with current SmPC
No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.)
Dated signature of informed consent form
Participation in Patient-Reported Outcome (PRO) assessment in German language and completion of questionnaire at time of study enrollment
Other criteria according to current Summary of Product Characteristics

You may not qualify if…

Participation in an interventional clinical trial (except follow-up)
Other contraindications according to current Summary of Product Characteristics

Where it is running

Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde — Hanover, Lower Saxony, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.